Pipeline Overview
Tengion is developing a diverse pipeline of novel cell and tissue based regenerative medicine therapies for patients who are experiencing organ and tissue impairment, failure and loss. Tengion's technology platform is designed to allow patients to have functioning organs and tissues regenerated from their own cells.
- Tengion Neo-Bladder Augment™ is under clinical investigation in two phase 2 clinical trials in patients with neurogenic bladder: pediatric patients with spina bifida and adult patients with spinal cord injury.
- Tengion Neo-Bladder Augment™ is also in pre-clinical and clinical development for other patient populations that have non-neurogenic bladder conditions refractory to medical therapy such as overactive bladder with associated urge incontinence.
- Tengion Neo-Bladder Replacement™ is in pre-clinical development as a bladder replacement for patients whose bladders are being removed surgically due to disease, such as bladder cancer, or impairment.
Tengion is leveraging its broad, innovative technology platform and has active research programs aiming to provide compelling clinical solutions for vascular and kidney related conditions.
- Tengion Neo-Vessel™ is our research program for alternative vascular access for patients undergoing dialysis, for patients who are undergoing peripheral bypass surgery and for patients undergoing coronary artery bypass surgery.
- Tengion Neo-Kidney™ is our research program for patients with chronic renal failure who are dependent on dialysis treatment and for patients who require medical treatment for chronic anemia.
Tengion's regenerative medicine product candidates are investigational and will not be commercially available until the completion of human clinical trials and the review and approval of associated marketing applications by the FDA.
Click here to check the status of Tengion's Pipeline »